Higher low-dose aspirin to prevent repeat preterm birth
A Dose Escalation Study of Low Dose Aspirin for the Prevention of Recurrent Preterm Birth
This project looks at whether giving higher daily low-dose aspirin early in pregnancy helps people who previously had a preterm birth avoid another early delivery.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11309996 on NIH RePORTER |
What this research studies
If you join, you'll be someone pregnant now who had a prior preterm birth and you'll start a daily aspirin pill early in pregnancy. Participants are assigned to different low-dose aspirin amounts to see which dose is safest and most helpful. The study includes regular clinic visits, monitoring for side effects, and tracking pregnancy outcomes like preterm delivery and high blood pressure disorders. Blood tests and safety checks will be used to watch for any problems during pregnancy.
Who could benefit from this research
Good fit: Ideal candidates are pregnant people with a history of a prior preterm birth who can start medication early in pregnancy and attend study visits.
Not a fit: People without a prior preterm birth, those with contraindications to aspirin (allergy, bleeding disorder, or taking certain blood thinners), or those already past the early pregnancy window may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lower the chances of having another preterm birth and reduce related pregnancy complications.
How similar studies have performed: Large trials and meta-analyses (including the ASPIRIN trial) have shown that low-dose aspirin can reduce preterm birth and preeclampsia, but whether higher early doses work better is less tested.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Clifton, Rebecca Gersnoviez — George Washington University
- Study coordinator: Clifton, Rebecca Gersnoviez
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.